Basic HTML Version
Conclusions
•
In this FIM study with a primary angiographic endpoint, the Orsiro Hybrid DES
showed excellent results in terms of late lumen loss in the overall patient
population
•
This mixed population of patients is atypical for a FIM study, with its high rate of
diabetic patients and complex lesions
•
At 9 months follow-up, no late catch-up was seen in the LLL values and a narrow
standard deviation suggests that these study results are quite robust
•
A larger randomized, comparative study is currently running to prove the safety
and effectiveness of this promising device